Ar­Qule’s lead drug tivan­ti­nib flops again in PhI­II liv­er can­cer study

Ar­Qule and Dai­ichi Sankyo’s tivan­ti­nib has come up short in an­oth­er Phase III study.

Five years af­ter the biotech’s lead drug flopped in a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.